With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
This is an exciting opportunity to join an expanding group supporting a growing pipeline of projects. Working closely with DMPK, pharmacology, safety and precision medicine colleagues in both discovery and development, you will define and lead the overall clinical pharmacology and model-informed drug development strategy across the portfolio, supporting late-stage preclinical and early clinical projects, but also working with the discovery phase projects to evaluate development strategies.
Specifically, you will work with project teams to apply clinical pharmacology and translational modelling approaches to our drug development projects providing PK/PD, and/or population PK study design, analysis interpretation and reporting to support drug discovery and development programs. You will contribute to IB/IND/CTA preparation, clinical trial and protocol design, biomarker strategy, disease and biomarker models, and take responsibility for FIH dose selection and Clinical DDI strategy.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email email@example.com. Thank you.